Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatits B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
Efficacy of pegylated interferon monotherapy versus sequential therapy of entecavir and pegylated interferon in Hepatitis B e antigen-Positive Hepatitis B Patients: A randomized, multicenter, phase IIIb Open-Label Study (POTENT Study)
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- CHINESE MEDICAL JOURNAL131(14) · pp.1645 · 2018
- 피인용
- Web of Science 7Scopus 8
- FWCI (Scopus)
- 0.59
- JCR IF
- JCR 2017 1.596
- ISSN
- 0366-6999
저자
- Jun, Dae Won제1저자Department of Internal Medicine, Hanyang University, Seoul Hospital, Seoul, South Korea
- Ahn, Sang BongDepartment of Internal Medicine, Nowon Eulji Hospital, Eulji University, Seoul, South Korea
- Kim, Tae YeobDepartment of Internal Medicine, Guri Hospital, Hanyang University, Guri, South Korea
- Sohn, Joo Hyun교신저자Department of Internal Medicine, Guri Hospital, Hanyang University, Guri, South Korea
- Kim, Sang GyuneDepartment of Internal Medicine, Bucheon Hospital, Soon Chun Hyang University, Bucheon, South Korea
- Lee, Se WhanDepartment of Internal Medicine, Cheonan Hospital, Soon Chun Hyang University, Cheonan, South Korea
- Kim, Byung HoDepartment of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, South Korea
- Kim, Dong JoonDepartment of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University, Chuncheon, South Korea
- Kim, Ja KyungDepartment of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University, Seoul, South Korea
- Kim, Hyoung SuDepartment of Internal Medicine, Gangnam Severance Hospital, Yonsei University, Seoul, South Korea
- Hwang, Seong GyuDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea
- Choi, Won ChoongDepartment of Internal Medicine, Sanggye Paik Hospital, Inje University, Seoul, South Korea
- Tak, Won YoungDepartment of Internal Medicine, Kyungpook National University Hospital, Kyungpook National University, Daegu, South Korea
- Lee, Heon JuDepartment of Internal Medicine, Yeungnam University Medical Center, Yeungnam University, Daegu, South Korea
- 윤기태Department of Internal Medicine, Yangsan Hospital, Pusan National University, Yangsan, South Korea
- Yun, Byung CheolDepartment of Internal Medicine, Gospel Hospital, Kosin University, Pusan, South Korea
- Lee, Sung WookDepartment of Internal Medicine, Dong A University Medical Center, Dong A University, Pusan, South Korea
- Baik, Soon KooDepartment of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University, Wonju, South Korea
- Park, Seung HaDepartment of Internal Medicine, Haeundae Paik Hospital, Inje University, Pusan, South Korea
- Park, Ji WonDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University, Anyang, South Korea
- Park, Sol JiDepartment of Clinical Pharmacy, Graduate School of Clinical Pharmacy, Sungkyunkwan University, Suwon, South Korea
- Lee, Ji SungClinical Research Center, Asan Medical Center, Seoul, South Korea
초록
Background: Until now, various types of combined therapy with nucleotide analogs and pegylated interferon (Peg-INF) in patients with hepatitis B patients have been tried. However, studies regarding the benefits of de novo combination, late-add on, and sequential treatment are very limited. The objective of the current study was to identify the efficacy of sequential treatment of Peg-INF after short-term antiviral treatment. Methods: Between June 2010 and June 2015, hepatitis B e antigen (HBeAg)-positive patients (n = 162) received Peg-IFN for 48 weeks (mono-treatment group, n = 81) and entecavir (ETV) for 12 weeks with a 48-week course of Peg-IFN starting at week 5 of ETV therapy (sequential treatment group, n = 81). The primary endpoint was HBeAg seroconversion at the end of follow-up period after the 24-week treatment. The primary endpoint was analyzed using Chi-square test, Fisher's exact test, and regression analysis. Results: HBeAg seroconversion rate (18.2% vs. 18.2%, t = 0.03, P = 1.000) and seroclearance rate (19.7% vs. 19.7%, t = 0.03, P = 1.000) were same in both mono-treatment and sequential treatment groups. The rate of alanine aminotransferase (ALT) normalization (45.5% vs. 54.5%, t = 1.12, P = 0.296) and serum hepatitis B virus (HBV)-DNA <2000 U/L (28.8% vs. 28.8%, t = 0.10, P = 1.000) was not different in sequential and mono-treatment groups at 24 weeks of Peg-INF. Viral response rate (HBeAg seroconversion and serum HBV-DNA <2000 U/L) was not different in the two groups (12.1% vs. 16.7%, t = 1.83, P = 0.457). Baseline HBV-DNA level (7 log(10)U/ml vs. 7.5 log(10)U/ml, t = 1.70, P = 0.019) and hepatitis B surface antigen titer (3.6 log(10)U/ml vs. 4.0 log(10)U/ml, t = 2.19, P = 0.020) were lower and predictors of responder in mono-treatment and sequential treatment groups, respectively. Conclusions: The current study shows no differences in HBeAg seroconversion rate, ALT normalization, and HBV-DNA levels between mono-therapy and sequential therapy regimens.
키워드
EntecavirHepatitis BPeginterferon Alfa-2aPEGINTERFERON ALPHA-2ACOMBINATION THERAPYLAMIVUDINETRIAL
식별자
- Scopus EID
- 2-s2.0-85049868704
- WoS UID
- 000438436100002



로그인
연구물 목록으로